Investigating gene-to-behavior pathways in psychiatric disorders: The use of a comprehensive behavioral test battery on genetically engineered mice

Annals of the New York Academy of Sciences

Volumn 1086, Issue , 2006, Pages 144-159

  Takao, Keizo ^a   Miyakawa, Tsuyoshi ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Animal model of schizophrenia; Calcineurin; Comprehensive behavioral test battery; Genetically engineered mice; Psychiatric diseases

Indexed keywords

CALCINEURIN; PROTEIN KINASE (CALCIUM,CALMODULIN);

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR; CATALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG PREFERENCE; DRUG SENSITIVITY; EMOTIONALITY; GENETIC ENGINEERING; GENETICS; LATENT INHIBITION; LEARNING; LOCOMOTION; MEMORY; MENTAL DISEASE; MOTIVATION; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PREPULSE INHIBITION; SCHIZOPHRENIA; SENSATION; SIGNAL TRANSDUCTION; SOCIAL INTERACTION; WORKING MEMORY; ANIMAL; HUMAN; MOTOR ACTIVITY; MOUSE MUTANT; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; REVIEW;

ANIMALIA; MUS;

ANIMALS; BEHAVIOR, ANIMAL; CALCINEURIN; HUMANS; MENTAL DISORDERS; MICE; MICE, MUTANT STRAINS; MOTOR ACTIVITY; PHENOTYPE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SIGNAL TRANSDUCTION;

EID: 34249733308     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1377.008     Document Type: Conference Paper

References (77)

1. MANN, C.C. 1994. Behavioral genetics in transition. Science 264: 1686-1689.
2. THOMPSON, S., A.R. CLARKE, A.M. POW, et al. 1989. Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells. Cell 56: 313-321.
3. SILVA, A.J., R. PAYLOR, J.M. WEHNER, et al. 1992. Impaired spatial learning in alpha-calcium-calmodulin kinase II mutant mice. Science 257: 206-211.
4. KLEE, C.B. 1991. Concerted regulation of protein phosphorylation and dephosphorylation by calmodulin. Neurochem. Res. 16: 1059-1065.
5. WINDER, D.G. & J.D. SWEATT. 2001. Roles of serine/threonine phosphatases in hippocampal synaptic plasticity. Nat. Rev. Neurosci. 2: 461-474.
6. ZENG, H., S. CHATTARJI, M. BARBAROSIE, et al. 2001. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 107: 617-629.
7. OLTON, D.S. & B.C. PAPAS. 1979. Spatial memory and hippocampal function. Neuropsychologia 17: 669-682.
8. MORRIS, R.G. & U. FREY. 1997. Hippocampal synaptic plasticity: role in spatial learning or the automatic recording of attended experience? Philos. Trans. R. Soc. Lond. B. Biol. Sci. 352: 1489-1503.
9. STEELE, R.J. & R.G. MORRIS. 1999. Delay-dependent impairment of a matching-toplace task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5. Hippocampus 9: 118-136.
10. GOLDMAN-RAKIC, P.S. 1996. Regional and cellular fractionation of working memory. Proc. Natl. Acad. Sci. USA 93: 13473-13480.
11. BOLHUIS, J.J., S. BIJLSMA & P. ANSMINK. 1986. Exponential decay of spatialmemory of rats in a radial maze. Behav. Neural. Biol. 46: 115-122.
12. DUDCHENKO, P.A. 2004. An overview of the tasks used to test working memory in rodents. Neurosci. Biobehav. Rev. 28: 699-709.
13. DALLEY, J.W., R.N. CARDINAL & T.W. ROBBINS. 2004. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci. Biobehav. Rev. 28: 771-784.
14. OLTON, D.S. 1983. The use of animal models to evaluate the effects of neurotoxins on cognitive processes. Neurobehav. Toxicol. Teratol. 5: 635-640.
15. SQUIRE, L.R. 1994. Memory and forgetting: long-term and gradual changes in memory storage. Int. Rev. Neurobiol. 37: 243-269; discussion 285-288.
16. MECK, W.H., R.M. CHURCH & D.S. OLTON. 1984. Hippocampus, time, andmemory. Behav. Neurosci. 98: 3-22.
17. CARAMANOS, Z. & M.L. SHAPIRO. 1994. Spatial memory and N-methyl-D-aspartate receptor antagonists APV and MK-801: memory impairments depend on familiarity with the environment, drug dose, and training duration. Behav. Neurosci. 108: 30-43.
18. CASSEL, J.C., S. CASSEL, R. GALANI, et al. 1998. Fimbria-fornix vs selective hippocampal lesions in rats: effects on locomotor activity and spatial learning and memory. Neurobiol. Learn. Mem. 69: 22-45.
19. CRAWLEY, J.N. 2000. What's Wrong With My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice. John Wiley & Sons. New York.
20. MIYAKAWA, T., T. YAGI, S. WATANABE, et al. 1994. Increased fearfulness of Fyn tyrosine kinase deficient mice. Brain Res. Mol. Brain Res. 27: 179-182.
21. MIYAKAWA, T., T. YAGI, H. KITAZAWA, et al. 1997. Fyn-kinase as a determinant of ethanol sensitivity: relation to NMDA-receptor function. Science 278: 698-701.
22. MIYAKAWA, T., T. YAGI, K. TAKAO, et al. 2001. Differential effect of Fyn tyrosine kinase deletion on offensive and defensive aggression. Behav. Brain Res. 122: 51-56.
23. MIYAKAWA, T., M. YAMADA, A. DUTTAROY, et al. 2001. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J. Neurosci. 21: 5239-5250.
24. MIYAKAWA, T., E. YARED, J.H. PAK, et al. 2001. Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components. Hippocampus 11: 763-775.
25. YAMADA, M., T. MIYAKAWA, A. DUTTAROY, et al. 2001. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410: 207-212.
26. MIYAKAWA, T., L.M. LEITER, D.J. GERBER, et al. 2003. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. USA 100: 8987-8992.
27. CALDARONE, B.J., C.H. DUMAN & M.R. PICCIOTTO. 2000. Fear conditioning and latent inhibition in mice lacking the high affinity subclass of nicotinic acetylcholine receptors in the brain. Neuropharmacology 39: 2779-2784.
28. WEINER, I. 2003. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl). 169: 257-297.
29. BRAUNSTEIN-BERCOVITZ, H., T. RAMMSAYER, H. GIBBONS, et al. 2002. Latent inhibition deficits in high-schizotypal normals: symptom- specific or anxiety-related? Schizophr. Res. 53: 109-121.
30. BRAFF, D.L. & M.A. GEYER. 1990. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47: 181-188.
31. PAYLOR, R. & J.N. CRAWLEY. 1997. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl) 132: 169-180.
32. SCHNEIDER, C.W. & M.B. CHENOWETH. 1970. Effects of hallucinogenic and other drugs on the nest-building behaviour of mice. Nature 225: 1262-1263.
33. BALLARD, T.M., M. PAULY-EVERS, G.A. HIGGINS, et al. 2002. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J. Neurosci. 22: 6713-6723.
34. LIJAM, N., R. PAYLOR, M.P. MCDONALD, et al. 1997. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell 90: 895-905.
35. CRAWLEY, J.N. 2004. Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment. Retard. Dev. Disabil. Res. Rev. 10: 248-258.
36. MORETTI, P., J.A. BOUWKNECHT, R. TEAGUE, et al. 2005. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum. Mol. Genet. 14: 205-220.
37. LAHTI, A.C., B. KOFFEL, D. LAPORTE, et al. 1995. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
38. JENTSCH, J.D. & R.H. ROTH. 1999. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225.
39. TAMMINGA, C.A., A.C. LAHTI, D.R. MEDOFF, et al. 2003. Evaluating glutamatergic transmission in schizophrenia. Ann. N. Y. Acad. Sci. 1003: 113-118.
40. NISHI, A., G.L. SNYDER & P. GREENGARD. 1997. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17: 8147-8155.
41. WEINBERGER, D.R. 1987. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44: 660-669.
42. LIPSKA, B.K., N.D. HALIM, P.N. SEGAL, et al. 2002. Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat. J. Neurosci. 22: 2835-2842.
43. HARRISON, P.J. & D.R. WEINBERGER. 2005. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10: 40-68; image 5.
44. CHANG, H.Y., K. TAKEI, A.M. SYDOR, et al. 1995. Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin. Nature 376: 686-690.
45. GRAEF, I.A., F. WANG, F. CHARRON, et al. 2003. Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell 113: 657-670.
46. LEWIS, D.A., L.A. GLANTZ, J.N. PIERRI, et al. 2003. Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons. Ann. N. Y. Acad. Sci. 1003: 102-112.
47. LAUER, M., S. JOHANNES, S. FRITZEN, et al. 2005. Morphological abnormalities in nitric-oxide-synthase-positive striatal interneurons of schizophrenic patients. Neuropsychobiology 52: 111-117.
48. BUNNEY, B.G., S.G. POTKIN & W.E. BUNNEY Jr.. 1995. New morphological and neuropathological findings in schizophrenia: a neurodevelopmental perspective. Clin. Neurosci. 3: 81-88.
49. CRABTREE, G.R. 2001. Calcium, calcineurin, and the control of transcription. J. Biol. Chem. 276: 2313-2316.
50. DE GROEN, P.C., A.J. AKSAMIT, J. RAKELA, et al. 1987. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N. Engl. J. Med. 317: 861-866.
51. CRAVEN, J.L. 1991. Cyclosporine-associated organic mental disorders in liver transplant recipients. Psychosomatics 32: 94-102.
52. BECHSTEIN, W.O. 2000. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl. Int. 13: 313-326.
53. TORREY, E.F. & R.H. YOLKEN. 2001. The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both? Brain Behav. Immun. 15: 401-410.
54. CUSH, J.J., P. TUGWELL, M. WEINBLATT, et al. 1999. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J. Rheumatol. 26: 1176-1186.
55. HENDERSON, D.C. & E.R. ETTINGER. 2002. Schizophrenia and diabetes. Int. Rev. Neurobiol. 51: 481-501.
56. DAVIDSON, M. 2002. Risk of cardiovascular disease and sudden death in schizophrenia. J. Clin. Psychiatry 63(Suppl 9): 5-11.
57. DOYLE, M.E. & J.M. EGAN. 2003. Pharmacological agents that directly modulate insulin secretion. Pharmacol. Rev. 55: 105-131.
58. OLSON, E.N. & R.S. WILLIAMS. 2000. Calcineurin signaling and muscle remodeling. Cell 101: 689-692.
59. HINZE-SELCH, D. & T. POLLMACHER. 2001. In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav. Immun. 15: 282-318.
60. ROTHERMUNDT, M., V. AROLT & T.A. BAYER. 2001. Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 15: 319-339.
61. MIRNICS, K., F.A. MIDDLETON, A. MARQUEZ, et al. 2000. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28: 53-67.
62. HAKAK, Y., J.R. WALKER, C. LI, et al. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA 98: 4746-4751.
63. YAKEL, J.L. 1997. Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. Trends Pharmacol. Sci. 18: 124-134.
64. COUSIN, M.A. & P.J. ROBINSON. 2001. The dephosphins: dephosphorylation by calcineurin triggers synaptic vesicle endocytosis. Trends Neurosci. 24: 659-665.
65. LAI, M.M., J.J. HONG, A.M. RUGGIERO, et al. 1999. The calcineurin-dynamin 1 complex as a calcium sensor for synaptic vesicle endocytosis. J. Biol. Chem. 274: 25963-25966.
66. KONTKANEN, O., P. TORONEN, M. LAKSO, et al. 2002. Antipsychotic drug treatment induces differential gene expression in the rat cortex. J. Neurochem. 83: 1043-1053.
67. RUDOLF, S., M. PETERS, M. ROTHERMUNDT, et al. 2002. The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferongamma in vitro. Neuropsychobiology 46: 180-185.
68. STRAUB, R.E., C.J. MACLEAN, Y. MA, et al. 2002. Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. Mol. Psychiatry 7: 542-559.
69. COON, H., M. MYLES-WORSLEY, J. TIOBECH, et al. 1998. Evidence for a chromosome 2p13-14 schizophrenia susceptibility locus in families from Palau, Micronesia. Mol. Psychiatry 3: 521-527.
70. CAMP, N.J., S.L. NEUHAUSEN, J. TIOBECH, et al. 2001. Genomewide multipoint linkage analysis of seven extended Palauan pedigrees with schizophrenia, by a Markov-chain Monte Carlo method. Am. J. Hum. Genet. 69: 1278-1289.
71. GERBER, DJ, D. HALL, T. MIYAKAWA, et al. 2003. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc. Natl. Acad. Sci. USA. 100: 8993-8998.
72. RUSHLOW, W.J., Y.H. SEAH, D.J. BELLIVEAU, et al. 2005. Changes in calcineurin expression induced in the rat brain by the administration of antipsychotics. J. Neurochem. 94: 587-596.
73. GREENGARD, P., P.B. ALLEN & A.C. NAIRN. 1999. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron. 23: 435-447.
74. SNYDER, S.H., D.M. SABATINI, M.M. LAI, et al. 1998. Neural actions of immunophilin ligands. Trends Pharmacol. Sci. 19: 21-26.
75. CRABTREE, G.R. 1999. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 96: 611-614.
76. AUSTIN, C.P., J.F. BATTEY, A. BRADLEY, et al. 2004. The knockout mouse project. Nat. Genet. 36: 921-924.
77. AUWERX, J., P. AVNER, R. BALDOCK, et al. 2004. The European dimension for the mouse genome mutagenesis program. Nat. Genet. 36: 925-927.